Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Bird Rock Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011838
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators. The company’s products under development include RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment of nonalcoholic steatohepatitis, fibrotic and metabolic diseases. Its Gerilimzumab, an anti IL-6 antibody indicated for moderate to severe rheumatoid arthritis, inflammatory and autoimmune diseases. Bird Rock Bio provides therapeutic antibodies, with clinical and commercial differentiation, against biologic targets. The company operates through research institutes and universities for its activities. Bird Rock Bio is headquartered in La Jolla, California, the US.

Bird Rock Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Partnerships 13
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Licensing Agreements 17
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc – Key Competitors 20
Bird Rock Bio Inc – Key Employees 21
Bird Rock Bio Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Clinical Trials 23
Jan 11, 2017: Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab 23
Jan 03, 2017: Bird Rock Bio Receives Approval from ANVISA and CONEP to Initiate the First Phase 2 Study in Brazil of Gerilimzumab for Rheumatoid Arthritis 24
Oct 27, 2016: Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab 25
Mar 15, 2016: argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody Against IL-6 to Treat Rheumatoid Arthritis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Bird Rock Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Bird Rock Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Bird Rock Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
RuiYi Raises US$15 Million In Series B Financing 10
Anaphore Secures US$0.15 Million In Venture Financing 12
Bird Rock Bio Enters into agreement with GE Healthcare 13
Janssen Pharma Enters into Partnership with Bird Rock Bio 14
RuiYi Enters into Agreement with iHuman Institute to Develop Novel Antibodies 15
CMC Biologics Enters Into Co-Development Agreement With RuiYi For RYI-008 Cell Line 16
Bird Rock Bio Enters into Licensing Agreement with arGEN-X for ARGX-109 17
RuiYi Enters Into Licensing Agreement With Genor BioPharma For RYI-008 19
Bird Rock Bio Inc, Key Competitors 20
Bird Rock Bio Inc, Key Employees 21

★海外企業調査レポート[Bird Rock Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SiteOne Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SiteOne Therapeutics Inc (SiteOne) is a biopharmaceutical company that develops novel non-opioid pain therapeutics for the treatment of acute and chronic pain. The company’s lead therapeutic candidates include ST-2427 Intravenous, for post-operative pain; ST-SubQ Subcutaneous and ST-Oral, fo …
  • Amgen Inc (AMGN)-医療機器分野:企業M&A・提携分析
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Cintas Corp (CTAS):企業の財務・戦略的SWOT分析
    Cintas Corp (CTAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Israel Chemicals Ltd.:企業のM&A・事業提携・投資動向
    Israel Chemicals Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Israel Chemicals Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Daiho Corporation:企業の戦略・SWOT・財務情報
    Daiho Corporation - Strategy, SWOT and Corporate Finance Report Summary Daiho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Pakistan Petroleum Ltd (PPL):企業の財務・戦略的SWOT分析
    Pakistan Petroleum Ltd (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Oxford BioMedica Plc (OXB):製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform o …
  • Lead Discovery Center GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Lead Discovery Center GmbH (LDC), a subsidiary of Max Planck Innovation GmbH is a biomedical research company that offers development of novel drugs and therapies. The company develops drugs and therapies for diseases such as neurodegenerative cardiovascular diseases, cancer, inflammatory di …
  • National Bank Of Kuwait Sak
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Avantium NV (AVTX):企業の財務・戦略的SWOT分析
    Avantium NV (AVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • John Paul Mitchell Systems Inc:企業の戦略・SWOT・財務情報
    John Paul Mitchell Systems Inc - Strategy, SWOT and Corporate Finance Report Summary John Paul Mitchell Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Asseco Poland SA (ACP):企業の財務・戦略的SWOT分析
    Summary Asseco Poland SA (Asseco) is a technology company that offers information processing solutions. The company offers banking, insurance companies, public institutions, healthcare, telecommunication, utilities, ERP solutions, IT infrastructure and others. Its IT infrastructure solutions include …
  • Covea Mutual Insurance Group Company:企業の戦略・SWOT・財務情報
    Covea Mutual Insurance Group Company - Strategy, SWOT and Corporate Finance Report Summary Covea Mutual Insurance Group Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Pirelli & C. S.p.A.:企業の戦略・SWOT・財務情報
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ImaBiotech SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary ImaBiotech SAS (ImaBiotech) is a contract research organization that offers mass spectrometry imaging services. The organization’s software products include quantinetix and multimaging. It offers services such as biomarker discovery, consulting and training, screening studies, target engagem …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • AeroMaoz Ltd.:企業の戦略・SWOT・財務情報
    AeroMaoz Ltd. - Strategy, SWOT and Corporate Finance Report Summary AeroMaoz Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tempur Sealy International, Inc.:企業の戦略・SWOT・財務情報
    Tempur Sealy International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tempur Sealy International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Cipla Ltd (CIPLA):医療機器:M&Aディール及び事業提携情報
    Summary Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetologi …
  • Marenica Energy Ltd (MEY):企業の財務・戦略的SWOT分析
    Summary Marenica Energy Ltd (MEY) is a mining and mineral resource exploration and development company that acquires, identifies, develops, and explores for lead, silver, zinc, copper, uranium and gold mineral properties in Australia. The company develops and operates uranium project using conventio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆